Browse > Article
http://dx.doi.org/10.7314/APJCP.2012.13.3.923

Early Efficacy of Endostar Combined with Chemoradiotherapy for Advanced Cervical Cancers  

Ke, Qing-Hua (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Zhou, Shi-Qiong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Huang, Min (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Lei, Yong (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Du, Wei (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Yang, Ji-Yuan (Department of Chemoradiotherapy, Oncology Hospital of Jingzhou)
Publication Information
Asian Pacific Journal of Cancer Prevention / v.13, no.3, 2012 , pp. 923-926 More about this Journal
Abstract
The aim of this study was to investigate the early outcome of Endostar combined with chemoradiotherapy for advanced cervical cancer. Fifty-two cases (FIGO IIb to IVa) were divided randomly into two groups, receiving chemoradiotherapy alone (CRT group) and Endostar combined with chemoradiotherapy (CRT+E group). For the patients in the CRT+E group, Endostar was administered daily with the dosage of 7.5 $mg/m^2$, and cisplatin was administered weekly with the dosage of 20 $mg/m^2$ during the radiation. The regimens lasted for 4 weeks with no difference in chemoradiotherapy between the two groups. The early outcome complete remission rate was 73.1%, partial remission rate was 23.1% and the total response rate was 96.2% in CRT+E group, a significant improvement on the 34.6%, 42.3% and 76.9%, respectively, in the CRT group. One year survive rates were 100% and 84.6% in the CRT+E group and CRT groups, the difference being significant. Endostar combined with chemoradiotherapy can improve the early outcome of the advanced cervical cancer, and adverse effects were not encountered.
Keywords
Cervical cancer; Endostar; chemoradiotherapy;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Brideau G, Makinen MJ, Elamaa H, et al (2007). Endostatin overexpression inhibits lymphangiogenesis and lymph node metastasis in mice. Cancer Res, 67, 11528-35.   DOI   ScienceOn
2 Duenas-Gonzale A, Zarba JJ, Alcedo JC, et al (2007). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.
3 Dubay RA, Rose PG, O'Malley DM, et al (2004). Evaluation of concurrent and adjuvant carboplatin with radiation therapy for locally advanced cervical cancer. Gynecol Oncol, 94, 121-4.   DOI
4 Duenas-Gonzalez A, Zarba JJ, Patel F, et al (2011). Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol, 29, 1678-85.   DOI
5 Eifel PJ, Winter K, Morris M, et al (2004). Pelvic irradiation with concurrent chemotherapy versus pelvic and paraaortic irradiation for high- risk cervical cancer: an update of radiation therapy oncology group trial (RTOG). 90-01. J Clin Oncol, 22, 872-80.   DOI   ScienceOn
6 Fukumoto S, Morifuji M, Katakury Y, et al (2005). Endostatin inhibits lymph node metastasis by a down- regulation of the vascular endothelial growth factor C expression in tumor cells. Clin Exp Metastasis, 22, 31- 8.   DOI   ScienceOn
7 Ge W, Cao DD, Wang HM, et al (2011). Endostar combined with chemotherapy versus chemotherapy alone for advanced NSCLCs: a meta-analysis. Asian Pac J Cancer Prev, 12, 2705-11.
8 Han BH, Xiu QY, Wang HM,et al (2011). A multicenter, randomized, double-blind, placebo-controlled safety study to evaluate the clinical effects and quality of life of paclitaxelcarboplatin (PC) alone or combined with endostar for advanced non-small cell lung cancer (NSCLC). Zhonghua Zhong Liu Za Zhi, 33, 854-9.
9 Han B, Xiu Q, Wang H, et al (2011). A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy of paclitaxel-carboplatin alone or with endostar for advanced non-small cell lung cancer. J Thorac Oncol, 6, 1104-9.   DOI
10 Jia Y, Liu M, Cao L, et al (2011). Recombinant human endostatin, Endostar, enhances the effects of chemo-radiotherapy in a mouse cervical cancer xenograft model. Eur J Gynaecol Oncol, 32, 316-24.
11 Li Y, Huang XE, Yan PW, et al (2010). Efficacy and safety of endostar combined with chemotherapy in patients with advanced solid tumors. Asian Pac J Cancer Prev, 11, 1119-23.
12 Li N, Jin ZL, Liu ZJ, et al (2011). Efficacy of endostar combined with chemotherapy in multi-cycle treatment of patients with advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi, 33, 937-42.
13 Lu P, Liang QD, Zheng QQ (2003). Influence of clinical and pathologic parameters on prognosis of cervical carcinoma in China. Chinese-German J Clin Oncol, 2, 163-5.
14 Sun Y, Shi YK (2007). 5 Edition. Beijing: People's Medical Publishing House. Manual Med Oncol, 142-624.
15 Rose PG,Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy ,or hydroxyurea during pelvic irradiation for locally advanced cervical cancer:a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10.   DOI   ScienceOn
16 Peters WA, Liu PY, Barrett RJ, et al (2000). Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high -risk early-stage cancer of the cervical. J Clin Oncol, 18, 1606-13.   DOI
17 Rose PG, Ali S, Watkins E, et al (2007). Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic Oncology Group Study. J Clin Oncol, 25, 2804-10.   DOI   ScienceOn
18 Rose PG, Bundy BN, Watkins EB, et al (1999). Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med, 340, 1144-53.   DOI   ScienceOn
19 Xin G, Du J, Zhu L, et al (2011). Differential anti-tumor effects for various regimens of endostar plus cisplatin in ovarian cancer. Zhonghua Yi Xue Za Zhi, 91, 3367-70.
20 Luo X, Liu W (2006). Endostar. Chinese J New Drugs, 15, 1893-5.
21 Yitao JIA , Zhongxin LI , Min LIU, et a1 (2009). Endostar reduces the growth and metastasis by inhibiting angiogenesis and lymphangiogenesis in nude mouse models of human cervical cancer. Chinese J Oncol, 31, 254-7.
22 Zhou JF, Bai CM, Wang YZ, et al (2011). Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study. Chin Med J, 124, 4299-303.